A Phase 3 interventional study of olverembatinib and Bosutinib in Chronic Myeloid Leukemia, CML and CML, Chronic Phase, sponsored by Ascentage Pharma Group Inc.. Recruiting at 163 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States — 48 open to participants now, 78 under way, 4 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States.
Among the 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, this one is the 20th largest by planned enrollment of the 449 interventional ones that give a count, is one of 14 that started in 2024, is one of 29 in phase 3, reaches primary completion later than 35 of the 77 other live ones, and was the 497th registered.
895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 107 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →48 of the 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States are open now. Recruiting first, the newest first:
Enliven Therapeutics · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 77 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 47 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
517 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 172 · Phase 2 277 · Phase 3 32 · Phase 4 7
First in 1992; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 333 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 36 across the 449 interventional studies, 142 across the 44 observational. Of the 409 that completed or were terminated, 195 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
128 of 517 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ascentage Pharma Group Inc., one of the names counted as Ascentage Pharma Group International. Under that name alone:
Ascentage Pharma Group Inc. is the lead sponsor of 53 studies on the registry; 31 are open to participants now.
Ascentage Pharma Group International has 4 studies filed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive — fewer than ten, so there is no comparison to draw.
22 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423911Phase 3Ascentage Pharma Group Inc.Study of Olverembatinib (HQP1351) in Patients With CML-CP | 2027-06-30 |
| NCT05362773MacroGenicsA Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | 2026-11 |
| NCT01890486Wake Forest University Health SciencesThe Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | 2026-12 |
| NCT06131801Children's Hospital Medical Center, CincinnatiPharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | 2026-12-01 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
Add all 22 to your calendar (.ics) → With an account.
Among the 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B).
Patients who meet ELN 2025 failure criteria while receiving bosutinib in Part A may be able to receive olverembatinib in crossover follow-on study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients eligible for inclusion in this study must meet all of the following criteria:
Exclusion Criteria
Patients eligible for this study must not meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized controlled part that is designed to compare the efficacy and safety of olverembatinib (investigational arm) versus bosutinib (control arm) in patients with CML-CP, previously treated with at least two TKIs
Drug: olverembatinib · Drug: Bosutinib
To evaluate the efficacy and safety of olverembatinib in the CML-CP patients with T315I mutation previously
Drug: olverembatinib
olverembatinib QOD
Bosutnib QD
24-Week MMR Rate (Part A)
To compare the major molecular response (MMR) rate at 24 weeks for olverembatinib versus bosutinib
Time frame: 24 weeks
24-Week MMR Rate (Part B)
To evaluate the MMR rate by 24 weeks for olverembatinib in CML-CP patients with T315I mutation
Time frame: 24 weeks
96-Week MMR Rate (Part A)
To compare the major molecular response (MMR) rate at 96 weeks for olverembatinib versus bosutinib
Time frame: 96 weeks
96-Week MMR Rate (Part B)
To evaluate the major molecular response (MMR) rate by 96 weeks for olverembatinib in CML-CP patients with T315I mutation
Time frame: 96 weeks
Cytogenic Response Rate (Part A)
To compare the complete cytogenic response rate at all scheduled data collection time points for olverembatinib vs. bosutinib.
Time frame: Through 96 weeks (i.e., at 24, 48, and 96 weeks)
Cytogenic Response Rate (Part B)
To evaluate the complete cytogenic response rate at all scheduled data collection time points for olverembatinib in CML-CP patients with T315I mutation
Time frame: Through 96 weeks (i.e., at 24, 48, and 96 weeks)
Progression Free Survival (PFS) (Part A)
To compare duration of PFS (i.e., from the date of randomization to the earliest occurrence of documented disease progression to AP/BP or the date of death from any cause) for olverembatinib versus bosutinib
Time frame: 5 years after the last patient received the first study dose
Progression Free Survival (PFS) (Part B)
To evaluate duration of PFS (i.e., from the date of enrollment to the earliest occurrence of documented disease progression to AP/BP or the date of death from any cause) for olverembatinib in CML-CP patients with T315I mutation
Time frame: 5 years after the last patient received the first study dose
Overall Survival (OS) (Part A)
To compare OS (duration from date of randomization to date of death) for olverembatinib versus bosutinib
Time frame: 5 years after the last patient received the first study dose
Overall Survival (OS) (Part B)
To evaluate OS (duration from date of randomization to date of death) for olverembatinib in CML-CP patients with T315I mutation
Time frame: 5 years after the last patient received the first study dose
Number of participants with treatment-emergent and treatment-related adverse events as assessed by CTCAE v5.0 (Parts A and B)
According to CTCAE v5.0, the number and frequency of adverse events for test drug will be assessed.
Time frame: 96 weeks after the last patient received the first study dose
Characterization of population pharmacokinetics of olverembatinib (Parts A and B)
Blood samples will be collected to measure the plasma concentration of olverembatinib
Time frame: At the end of Cycle 1 and Cycle 2 (each cycle is 28 days)
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 163 sites across 16 countries. Choose a country and city above to see the rest.
Started Feb 2024 (actual). Primary completion is estimated for Jun 2027, 40 months after the start.
Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's planned 40 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →